Del Labs merger
This article was originally published in The Tan Sheet
Kelso & Company subsidiary DLI Acquisition Corp. completes purchase of Del Labs following shareholder approval, Del announces Jan. 27. Under the $480 mil. transaction, Del will become a subsidiary of DLI Holding Corp. and will no longer be publicly traded. William McMenemy will replace Dan Wassong as president and CEO. The deal was first announced last July (1"The Tan Sheet" July 5, 2004, p. 10)...
You may also be interested in...
Church & Dwight will augment its oral care portfolio with the addition of Del Labs' Orajel topical analgesic brand under a proposed $465 mil. acquisition announced July 2
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.